Apogenix‘s lead candidate APG101, which has shown great results in a phase II study to treat Glioblastoma, has a new target in line. But this time, it’s not against cancer…
Apogenix is a Germany-based company developing innovative immuno-oncology therapeutics for cancer and other malignant diseases. It was founded in 2005 and has raised over €90M until now.
Its lead candidate APG101 is a fusion protein that consists of the Fc domain of an IgG antibody and the extracellular domain of the CD95 receptor, which is present in many tumor cells. Once the CD95 ligand is blocked, it induces the death of the malignant cell. This first success had guaranteed €3M from the CancerMark project, which was initiated earlier this year.
But as in many other cases, this ligand is involved in more than one biological process. For instance, blocking the CD95 ligand results in an increased production of erythrocytes (red blood cells), which can be useful in some cases of Myelodysplastic Syndromes (MDS).